Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Dilutive issuance
confidence 92%
filed 2026-08-28
Item 8.01
Coherus Oncology entered into an at-the-market (ATM) sales agreement with Leerink Partners to offer and sell up to $50 million of common stock shares. This is a dilutive equity issuance under Rule 415(a)(4) of the Securities Act, disclosed via Item 8.01. The filing explicitly describes an "at the market offering" mechanism and establishes the framework for unregistered or registered equity sales that would dilute existing shareholders, making this material to investors assessing capital structure and ownership stakes.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-28
EX-99.2
Hafnia Limited announced financial results for Q2 2026 and H1 2026, reporting net profit of USD 277.8 million for Q2 and USD 457.5 million for H1, along with detailed operational metrics and fleet information.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 98%
filed 2026-08-28
EX-99.3
Hafnia Limited declared a cash dividend of USD 0.5003 per share for Q2 2026, approved on 27 August 2026, with record date of 8 September 2026 and payment dates for shares on both the Oslo Stock Exchange and Depository Trust Company.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-28
Item 7.01
T. Rowe Price OHA Select Private Credit Fund declared regular distributions of $0.20 per share gross for all classes of common shares, with a record date of August 31, 2026 and payment date of September 30, 2026.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-08-28
Item 8.01
Roivant disclosed FDA approval and commercial launch of LISRAYA (brepocitinib) for dermatomyositis treatment on August 28, 2026. This is a material regulatory milestone and product commercialization event—the company's first approved drug product—but does not fit the specific taxonomy categories. While it is clearly operational/strategic in nature (product approval and launch), it is not a traditional M&A activity, workforce reduction, or material contract. The disclosure centers on regulatory approval achievement and immediate commercial availability, making it a significant operational milestone for the company.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-28
Item 5.07
This Item 5.07 discloses the results of a special shareholder meeting held on August 28, 2026, where Crinetics shareholders voted on three proposals, most critically the merger with Vertex Pharmaceuticals. Proposal No. 1 (the Merger Proposal) was approved with 79,240,098 votes in favor versus 13,618 against, satisfying the final outstanding condition to close the merger. The filing explicitly states the approval "satisfies the final outstanding condition to the closing of the Merger" and anticipates closing on or about September 1, 2026, making this a material M&A milestone disclosed through shareholder vote results.
View raw filing on EDGAR →
6-K
Delisting risk
confidence 85%
filed 2026-08-28
EX-99.1
The press release announces XORTX's voluntary delisting from the TSX Venture Exchange, expected to take effect September 1, 2026. While framed as a cost-reduction measure, a delisting materially affects the registrant's listing status and investor access to trading venues. The disclosure also includes a corrective disclosure of US$240,000 in finder's fees related to the Vectus acquisition that were inadvertently omitted from the April 2026 announcement, which is a material accounting correction. The primary event is the delisting announcement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-08-28
EX-99.1
This press release announces completion of the first underground blast at Anfield's Velvet-Wood uranium and vanadium mine in nearly 40 years, along with progress on rehabilitation work (decline rehabilitation, water treatment plant construction, and dewatering infrastructure). While this represents a significant operational milestone in advancing the project toward production, it does not fit the specific event-type categories (not an earnings release, M&A activity, impairment, litigation, or other named events). The disclosure is material because it demonstrates concrete progress on a key asset in the company's hub-and-spoke strategy and signals movement toward the next development phase, which would affect a reasonable investor's assessment of the company's operational trajectory and near-term production prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-28
EX-99.1
This exhibit is a corporate presentation disclosing Aura Minerals' operational and strategic portfolio overview, including production guidance (340k–390k GEO in 2026), asset details, cost metrics, capital investment plans, and development milestones for multiple mining projects (Borborema, Era Dorada, Matupá, MSG). While it contains forward-looking statements and operational metrics typical of investor presentations, it does not constitute a discrete event (such as M&A, executive change, or debt issuance) nor a periodic financial report with audited statements. The presentation highlights operational improvements, capacity expansions, and project construction progress—material operational and strategic disclosures that would affect a reasonable investor's assessment of the company's growth trajectory and execution capability.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-08-28
EX-99.1
Algonquin announced an agreement to sell its approximately 64% ownership stake in Chilean water utility Suralis S.A. to Toesca for $126.5 million plus up to $1.5 million earnout. This is a material disposition of a significant asset that will be used for debt paydown and capital recycling into the company's core regulated utility businesses, representing a strategic simplification of geographic footprint.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-28
EX-99
BioLineRx announced a $3.75 million registered direct offering of 1,348,921 ADSs at $2.78 per ADS, plus concurrent private placement of warrants to purchase 2,023,382 ADSs at the same price. This is a classic dilutive equity issuance raising capital through unregistered (private placement) and registered direct offerings. The company explicitly states the offering is expected to close August 31, 2026, and intends to use proceeds for R&D and working capital—typical of a cash-raising capital event at a clinical-stage biotech.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 95%
filed 2026-08-28
The 6-K body discloses a final dividend of 99 US cents per ordinary share for the full year ended 30 June 2026, determined by the Board on 18 August 2026 and payable on 23 September 2026. This is a material capital distribution to shareholders. The filing includes currency exchange rates for South African Rand conversion and tax withholding details, confirming this is a substantive dividend announcement affecting shareholder returns.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-28
EX-99
This is a press release announcing Jiayin Group's unaudited financial results for the second quarter ended June 30, 2026. The exhibit discloses quarterly net revenue (RMB736.9 million, down 60.9% YoY), net loss (RMB183.6 million vs. net income of RMB519.1 million in Q2 2025), and key operational metrics including transaction volume, delinquency ratios, and per-share results. The dramatic reversal from profitability to loss, combined with a 74.4% decline in transaction volume, is material to investors' assessment of the company's financial condition and operational performance.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 75%
filed 2026-08-28
Item 7.01
The filing announces the redemption of all outstanding shares of MAA's 8.50% Series I Cumulative Redeemable Preferred Stock on October 1, 2026, at $50.00 per share plus accrued dividends. While this is technically a capital structure transaction involving preferred equity retirement, the core disclosed action is a return of capital to preferred shareholders—the redemption price and final dividend payment constitute a distribution. The company explicitly notes this is a "targeted capital structure initiative" funded through an ATM offering, and the transaction is expected to be accretive to Core FFO per share, making it material to investors assessing the company's capital allocation and financial position.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-28
Item 5.02
Kelly Rooney, Executive Vice President and Chief Operating Officer, resigned effective mid to late September 2026 to pursue other career opportunities. The disclosure centers on her departure from a senior executive role, with no successor immediately appointed to the COO position—instead, two SVPs will assume interim operational oversight. This is a material executive departure affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-08-28
Item 8.01
Cytokinetics announced positive Phase 3 clinical trial results for aficamten (ACACIA-HCM) in non-obstructive hypertrophic cardiomyopathy, with plans to submit a supplemental New Drug Application to the FDA in Q4 2026. While this is a significant clinical and regulatory milestone for the company's pipeline, it does not fit neatly into the earnings_release category (which typically covers financial results) nor any other specific event type. The disclosure centers on a material clinical development and regulatory milestone that would affect investor assessment of the company's prospects, making it a material operational/strategic event.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-28
Item 7.01
The filing discloses a declared distribution of $0.0864 per common share by Fidelity Core Real Estate Fund, payable to shareholders of record on August 31, 2026, with payment on or about September 22, 2026. This is a routine but material dividend distribution to shareholders, consistent with the fund's regular distribution practice. The disclosure is made under Item 7.01 (Regulation FD Disclosure) rather than a dedicated Item, but the substance is clearly a dividend declaration.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
CVC-PE Global Private Equity Fund, LP sold approximately $37.0 million in unregistered limited partnership units on August 1, 2026, as part of a continuous private offering exempt from Securities Act registration under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-08-28
Item 8.01
XTO Energy Inc., a wholly-owned subsidiary of ExxonMobil Holdings Corporation, issued redemption notices on August 28, 2026 calling for full redemption of three series of senior notes totaling approximately $626.5 million in aggregate principal ($174.4M 2036 Notes, $252.4M 2037 Notes, $199.7M 2038 Notes) on September 27, 2026 at 100% of principal plus accrued interest and a make-whole amount. While technically a redemption (retirement) of existing debt rather than issuance of new debt, this represents a material modification of the company's direct financial obligations and capital structure. The event is material as it involves a significant cash outlay and restructuring of the company's debt portfolio.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-28
Item 3.02
The Company sold 83,485.841 Class I common shares for approximately $1.7 million in an unregistered offering exempt under Section 4(a)(2) and Regulation D/S, representing a material capital raise that increases share count and dilutes existing shareholders.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-28
Item 8.01
The Company declared a regular monthly distribution for August 2026 of $0.15 per share for Class I Shares, payable to shareholders of record as of August 25, 2026, with payment on or about September 9, 2026.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 3.02
Macquarie Infrastructure Fund sold approximately $2,050,000 of unregistered Class I limited partnership units to accredited investors and qualified purchasers under Section 4(a)(2) and Regulation D as part of a continuous private offering.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-08-28
Item 8.01
The Board of Directors has authorized a distribution to stockholders of record as of August 31, 2026, with specific per-share amounts for each class of common stock (ranging from $0.0872 to $0.1042 net per share depending on class). The distributions are payable on or about September 3, 2026, and may be paid in cash or reinvested through the company's distribution reinvestment plan. This is a clear dividend/distribution declaration material to investors in a real estate income trust.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-08-28
Item 5.02
John Brottem, General Counsel of Outset Medical, informed the Company on August 27, 2026 of his decision to depart effective September 11, 2026, to pursue other professional opportunities. The disclosure centers on the departure of a named officer from his role, with explicit confirmation that the departure is not due to dispute or disagreement. This is a clear executive departure event material to investors assessing the registrant's leadership and governance.
View raw filing on EDGAR →
8-K
Bankruptcy Filing
confidence 95%
filed 2026-08-28
Item 1.03
Sangamo Therapeutics filed a voluntary Chapter 11 petition on June 23, 2026, in the U.S. Bankruptcy Court for the District of Delaware (case number 26-10989), representing a terminal event materially threatening the registrant's continued existence.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-28
Item 1.01
Sangamo Therapeutics entered into a material definitive asset purchase agreement with PTC Therapeutics for the sale of certain assets, disclosed in connection with the Chapter 11 bankruptcy filing.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 82%
filed 2026-08-28
Item 2.03
Pool Corporation amended its receivables securitization facility, extending the termination date to August 25, 2028 and increasing the maximum facility limit to $400 million. This amendment creates or materially modifies a direct financial obligation and is material to investors assessing the company's liquidity and capital structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-08-28
Item 5.02
The disclosure centers on the Board's appointment of Alicia Pfeifer and Brett Coburn as co-Chief Financial Officers on an interim basis, effective September 1, 2026. While the section also includes compensatory details (a $10,000 monthly stipend), the principal disclosed action is the appointment of these two executives to a material C-suite role. This is a significant leadership change affecting the company's financial reporting structure and would materially affect a reasonable investor's assessment of the registrant.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-08-28
Item 8.01
The filing discloses authorization and declaration of distributions to common stockholders across multiple share classes (A, D, I, P, T) with a record date of August 31, 2026 and payment on September 17, 2026, plus a quarterly dividend on the 6.75% Series A Cumulative Redeemable Preferred Stock payable September 30, 2026. These are routine but material periodic distributions typical of a real estate investment trust (REIT), affecting shareholder returns and capital allocation.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 97%
filed 2026-08-28
Item 2.03
Choice Hotels International entered into a $500 million senior unsecured credit agreement with Wells Fargo Bank as administrative agent and a syndicate of lenders on August 28, 2026, with a maturity date of August 28, 2029. This represents a material creation of a new direct financial obligation that affects the company's capital structure and financial flexibility.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-08-28
Item 1.01
On August 26, 2026, Karman Holdings entered into a Sixth Amendment to its Credit Agreement, increasing the principal amount of term loans by $100 million to a total of $863.961 million. The proceeds are earmarked for the Walker Precision Engineering acquisition and related transaction costs.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-08-28
Item 8.01
Karman Holdings completed its previously announced acquisition of Walker Precision Engineering for approximately $95 million in cash. Walker provides advanced products for EU tactical missile programs and expands the Company's European footprint with complementary IP and technology.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-08-28
Item 5.07
This is a clear disclosure of shareholder voting results from Central Plains Bancshares' Annual Meeting of Stockholders held on August 25, 2026, covering three matters: election of directors (Steven D. Kunzman, Daniel D. Naranjo, and Francis E. Younes), ratification of Plante & Moran, PLLC as independent auditor, and approval of a share repurchase proposal. The tabulated vote counts for each proposal are the hallmark of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →
8-K
Financial Other
confidence 72%
filed 2026-08-28
Item 8.01
The filing discloses Amendment No. 11 to Vroom's Warehouse Credit Facility, which extends the Commitment Termination Date by one month (from August 28, 2026 to September 30, 2026). This is a material amendment to a direct financial obligation—a warehouse credit facility used for auto financing operations. While the amendment itself is routine (a short extension with no other material terms changed), the timing and need for extension may signal liquidity or refinancing considerations material to investors assessing the company's financial position.
View raw filing on EDGAR →
8-K
Financial Other
confidence 85%
filed 2026-08-28
Item 8.01
This Item 8.01 disclosure recasts prior financial statements to reflect the March 25, 2026 sale of Hecla Quebec (Casa Berardi mine) to Orezone Gold Corporation for $602.2 million undiscounted consideration. The filing reclassifies Casa Berardi as a discontinued operation and updates income statement presentation across the 2025 Form 10-K and Q1 2026 Form 10-Q. While the underlying transaction (the sale itself) would be an M&A activity, this specific 8-K is a restatement of presentation and classification of prior financial statements to reflect that completed disposition, making it a financial restatement-adjacent disclosure. The company explicitly states this represents "a strategic shift that has a major effect on our operations and financial results," confirming materiality.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-08-28
Item 5.02
IonQ appointed two new directors to its Board of Directors effective August 24, 2026: Dr. Eric R. Ball, who brings 40 years of senior financial experience at AT&T, Cisco, and Oracle, and Timothy E. Baxter, with 40+ years leading major technology companies including as Samsung CEO. Both appointments are material governance events reflecting strategic leadership additions to support IonQ's quantum computing manufacturing expansion.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-08-28
Item 8.01
The filing discloses a distribution made on August 17, 2026, to holders of certificates issued by the Trust. The Trustee's Distribution Statement (Exhibit 99.1) shows a cash distribution of $431,333.10 from the Interest Account to certificate holders. This is a routine periodic distribution of income to security holders, consistent with the dividend_distribution event type.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-08-28
Item 2.03
PowerCompute entered into a Loan and Security Agreement with Arch Lending on August 25, 2026, creating a $21.9 million direct financial obligation secured by 307 Bitcoin at 6.5% interest under a 30-day collar loan structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-08-28
Item 1.01
This Item 1.01 discloses Amendment No. 1 to the Merger Agreement between Boundless Bio, Merger Sub, and Serapha Bio, dated August 28, 2026. The amendment modifies key terms of a previously announced merger transaction, including treatment of Serapha RSUs, issuance of pre-funded warrants as merger consideration, and voting standards for share authorization. This is a material amendment to an ongoing M&A transaction that would materially affect the terms and consideration structure of the contemplated merger.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-08-28
Item 1.01
Spero Therapeutics entered into an Open Market Sale Agreement with Jefferies to conduct an at-the-market (ATM) offering of up to $100 million in common stock under a universal shelf registration statement, representing a material dilutive equity issuance.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-28
Item 3.01
Gulf Resources received a notice from Nasdaq on August 24, 2026 indicating non-compliance with Listing Rule 5250(c)(1) due to failure to timely file its Q2 2026 Form 10-Q. The company is required to submit a compliance plan and remains delinquent on multiple periodic filings (Q1 and Q2 2026 10-Qs). This is a classic delisting-risk disclosure under Item 3.01, as the company faces potential delisting if it fails to regain compliance with Nasdaq's continued listing standards.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 85%
filed 2026-08-28
EX-99.1
INX Limited announces the calculation of its pro rata portion of the Distributable Amount per INX Token as of June 30, 2026, with an indicative distribution of $0.24145 per token. This is a contractual distribution obligation to token holders based on 40% of cumulative Adjusted Operating Cash Flow, functionally equivalent to a dividend or distribution to security holders. The disclosure of the calculated distributable amount and per-token distribution rate constitutes a material announcement of a distribution event, even though the company notes it is still in the process of distributing funds from a prior acquisition-related cash distribution event.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 85%
filed 2026-08-28
The 6-K discloses filing of a prospectus supplement on August 28, 2026, reducing the maximum aggregate offering price of American Depositary Shares (ADSs) under a Sales Agreement with Leerink Partners from $100 million to $80 million. This represents a material modification to an at-the-market (ATM) equity offering facility, which is a dilutive issuance mechanism. The reduction in offering capacity is a material capital-raising event affecting shareholder dilution potential.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-28
EX-99.1
This is a press release announcing the timing and logistics of MoneyHero's second quarter 2026 financial results disclosure scheduled for September 11, 2026. Although the actual results have not yet been released, the announcement of an imminent earnings release and conference call is a standard earnings-release disclosure. The document explicitly states "MoneyHero Group to Announce Second Quarter 2026 Results" and provides the date, time, and webcast/call registration details, making this a material event that would inform investors of when to expect quarterly financial performance data.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-08-28
Item 1.01
Pluri Inc. entered into a securities purchase agreement on August 26, 2026, to issue 1,200,000 common shares at $1.50 per share, 1,028,940 pre-funded warrant shares, and 2,228,940 common purchase warrants in a registered direct offering and concurrent private placement, raising approximately $2.98 million in net proceeds. The transaction includes an unregistered private placement of common warrants and underlying common stock pursuant to Section 4(a)(2) and Regulation D, representing a material dilutive equity issuance affecting shareholder ownership and capital structure.
View raw filing on EDGAR →
6-K
Dividend Distribution
confidence 92%
filed 2026-08-28
EX-99.1
GCL announced a Board-authorized share repurchase program for up to $10 million over the next 12 months. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution category, which encompasses "share-repurchase programs" alongside dividends and distributions. The $10 million authorization and CEO statement about shareholder value creation are material to investor assessment of capital allocation policy.
View raw filing on EDGAR →
6-K
Dilutive issuance
confidence 95%
filed 2026-08-28
The 6-K discloses three tranches of unregistered securities issuances totaling $3 million in August 2026 under an existing securities purchase agreement with Alpha Capital Anstalt. The Company issued convertible preferred shares and ordinary warrants in private placements pursuant to Section 4(a)(2) and Regulation D Rule 506(b) exemptions. This represents dilutive equity financing typical of small-cap issuers raising capital through private placements, with the securities to be registered for resale under multiple F-3 and S-8 registration statements.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-08-28
Item 8.01
The filing discloses that Nasdaq's Staff determined the Company should be delisted, trading was suspended on August 26, 2026, and the Company has scheduled a hearing before the Nasdaq Hearings Panel on September 29, 2026 to appeal the delisting determination and request continued listing. The Company explicitly acknowledges "there can be no assurance that the Panel will grant the Company's request for continued listing," indicating material delisting risk under Item 8.01.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-28
EX-99.2
This exhibit is a preliminary results announcement for Immuron's financial year ending 30 June 2026, disclosing FY26 Net Sales of A$7.7 million (6% growth), Net Profit improvement of A$1.4 million, and Cash increase of A$6.2 million. The document explicitly states "Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to release its preliminary results for financial year ending 30 June 2026" and includes detailed financial metrics and operational milestones. This is a discrete earnings announcement, not a periodic financial report filing itself.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-08-28
EX-99.1
This press release announces SuperX's receipt of a 128-unit B300 AI server purchase order from Ezisight Australia, marking the company's "official entry into the Australian market" and described as "a substantive business breakthrough" and "key milestone in the Company's Asia-Pacific business expansion." While this is a material commercial contract and market-entry event, it does not fit the specific operational categories (workforce reduction, restructuring) or other defined event types. The disclosure is clearly operational and strategic in nature—a significant customer order and geographic expansion—making it material to a reasonable investor's assessment of the company's growth trajectory and market presence.
View raw filing on EDGAR →